Radionuclide-based theranostics - a promising strategy for lung cancer.

Abstract

This review aims to provide a comprehensive overview of the latest literature on personalized lung cancer management using different ligands and radionuclide-based tumor-targeting agents. Lung cancer is the leading cause of cancer-related deaths worldwide. Due to the heterogeneity oflung cancer, advances in precision medicine may enhance the disease management landscape.More recently, theranostics using the same molecule labeled with two different radionuclides forimaging and treatment has emerged as a promising strategy for systemic cancer management. Inradionuclide-based theranostics, the target, ligand, and radionuclide should all be carefullyconsidered to achieve an accurate diagnosis and optimal therapeutic effects for lung cancer. We summarize the latest radiotracers and radioligand therapeutic agents used in diagnosing andtreating lung cancer. In addition, we discuss the potential clinical applications and limitationsassociated with target-dependent radiotracers as well as therapeutic radionuclides. Finally, weprovide our views on the perspectives for future development in this field. Radionuclide-based theranostics show great potential in tailored medical care. We expect thatthis review can provide an understanding of the latest advances in radionuclide therapy for lungcancer and promote the application of radioligand theranostics in personalized medicine.